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Immunohistochemical analyses of the effects of hepatocyte growth factor (HGF) and c-Met expression on tumour growth and
angiogenesis were performed on 88 patients with non-small-cell lung cancers (NSCLCs). In all, 22 carcinomas (25.0%) were
intratumoral HGF-positive, 14 carcinomas (15.9%) were stromal HGF-positive, and 36 carcinomas (40.9%) were intratumoral c-Met-
positive. None of the carcinomas were stromal c-Met-positive. Examination of tumour growth revealed that the frequency of
tumours with a high Ki-67 index was significantly greater for stromal HGF-positive tumours than for stromal HGF-negative tumours
(P¼0.0197). The frequency of tumours with a high Ki-67 index was also significantly greater for intratumoral c-Met-positive tumours
than for intratumoral c-Met-negative tumours (P¼0.0301). However, there was no significant difference in tumour vascularity with
relation to intratumoral HGF status, stromal HGF status, and intratumoral c-Met status. The survival rate of patients with intratumoral
c-Met-positive tumours was significantly lower than for patients with c-Met-negative tumours (P¼0.0095). Furthermore, the survival
rate of patients with both intratumoral c-Met-positive and stromal HGF-positive tumours was significantly lower than for patients with
either positive tumours, and that of patients with both negative tumours (P¼0.0183 and P¼0.0011, respectively). A univariate
analysis revealed that intratumoral c-Met expression was a significant prognostic factor of NSCLC patients (relative risk¼2.642,
P¼0.0029). The present study demonstrates that tumour–stromal interaction between tumour cell-derived c-Met and stromal cell-
derived HGF affects tumour growth and the prognosis of NSCLC patients.
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Non-small-cell lung cancer (NSCLC) is one of the most common
human malignancies with a poor prognosis. It is widely accepted
that malignant tumours are caused by the accumulation of genetic
alterations, which reflect the biological behaviour of tumours, such
as aggressive cell proliferation as well as invasive and metastatic
potential (Cordon-Cardo, 1995). Therefore, it is considered
important to understand the biological behaviour of NSCLCs, to
improve the clinical outcome of NSCLC patients.
Tumour–stromal interaction is an essential part of malignant
progression in vivo (Chung, 1995). During tumour development,
stromal fibroblasts produce an extracellular matrix that is used as
an anchorage by tumour cells. In addition, the extracellular matrix
also functions as a reservoir of growth factors derived from
tumour or stromal cells. Various growth factors and their
receptors, including hepatocyte growth factor (HGF)/c-Met,
epithelial growth factor (EGF)/EGF-R, and the vascular endothelial
growth factor (VEGF) family/VEGF-Rs, are reported to be involved
in tumour–stromal interactions (Nakamura et al, 1997; Turkeri
et al, 1998; Kajita et al, 2001).
Among these growth factors and their receptors, the HGF/c-Met
pathway has multiple biological functions, such as cell prolifera-
tion (Montesano et al, 1991), motility (Weidner et al, 1990),
angiogenesis (Bussolino et al, 1992), and morphogenesis (Brink-
mann et al, 1995). Many human cancers exhibit overexpression of
HGF and/or c-Met (Olivero et al, 1996; Kurimoto et al, 1998;
Edakuni et al, 2001), and several clinical studies revealed that
overexpression of HGF and/or c-Met is associated with the
prognosis of NSCLC patients (Ichimura et al, 1996; Takanami
et al, 1996; Siegfried et al, 1997). However, the mechanisms of their
biological behavior in NSCLCs are not fully understood in part
because they have multiple functions.
To clarify the role of HGF/c-Met in NSCLCs, we undertook a
clinical study of HGF and c-Met expression in relation to tumour
growth and vascularity. We evaluated their expression using
immunohistochemistry to differentiate tumour cell-derived ex-
pression from stromal cell-derived expression. In addition, we
studied their effects on cell proliferation rate using the Ki-67
labeling index (Gerde et al, 1984; Scagliotti et al, 1993) and their
ability to promote tumour angiogenesis was evaluated by
intratumoral microvessel density (IMD) using CD34 staining
(Matsuyama et al, 1998).
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Clinical characteristics of patients
NSCLC patients who underwent surgery at the Second Department
of Surgery, Kagawa Medical University, from January 1993 to
March 2001, were examined. Tumour-node-metastasis (TNM)
staging designations were assigned according to the postsurgical
pathological international staging system (Mountain, 1997). Since
Stage IV-lung cancer involves several ill-defined factors and has
distant metastases, patients with these signs were excluded from
the study. Patients with two or more types of cancers and patients,
who died of causes other than NSCLC, were also excluded. In total,
88 NSCLC patients were investigated. Among them were 46
patients with adenocarcinoma, 29 patients with squamous cell
carcinoma, and 13 patients with large-cell carcinoma. Patients’
clinical records and histopathological diagnoses were fully
documented. This report includes follow-up data until May 27,
2003. The mean follow-up period for all patients was 49.8736.1
months.
Immunohistochemical staining of HGF, c-Met, Ki-67, and
CD34
We used a rabbit polyclonal antibody against HGF (SC-7949, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) at 1:100 dilution, a
rabbit polyclonal antibody against c-Met (SC-10, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) at 1:100 dilution, a
mouse monoclonal antibody against Ki-67 (MIB-1, DAKO,
Glostrup, Denmark) at 1:40 dilution, and a mouse monoclonal
antibody against CD34 (NU-4A1, Nichirei Corporation, Tokyo,
Japan) at 1:10 dilution.
Formalin-fixed paraffin-embedded tissue was cut into 4-mm-
thick sections and mounted on poly-L-lysine-coated slides.
Sections were then deparaffinized and rehydrated, heated in a
microwave for 10min in a 10-mmoll
 1 citrate buffer solution at pH
6.0, and cooled to room temperature for 20min. After quenching
endogenous peroxidase activity with 0.3% H2O2 (in absolute
methanol) for 30min, the sections were treated for 2h at room
temperature with 5% bovine serum albumin to block nonspecific
staining. The sections were subsequently incubated overnight with
primary specific antibodies against HGF, c-Met, Ki-67, and CD34,
respectively. The slides were then incubated for 1h with
biotinylated anti-rabbit IgG (Vector Laboratories Inc., Burlingame,
CA, USA) against HGF and c-Met, and biotinylated anti-mouse IgG
(Vector Laboratories Inc., Burlingame, CA, USA) against Ki-67 and
CD34. The sections were incubated with the avidin–biotin–
peroxidase complex (Vector Laboratories Inc.) for 1h, and
antibody binding was visualized with 3,30-diaminobenzidine
tetrahydrochloride. As a final step, the sections were counter-
stained with Mayer’s haematoxylin. Sections of resected lung
tumours known to express HGF and c-Met were used as positive
controls for immunostaining, and sections incubated with normal
rabbit IgG served as negative reaction controls for staining of HGF
and c-Met.
All immunostained sections were reviewed by two pathologists
(RH and MU) who had no knowledge of the patients’ clinical
status. Cases with discrepancies were jointly reevaluated and a
consensus was reached. In cases with multiple areas of low
intensity that occurred during evaluation of immunostaining of
HGF and c-Met, five areas were selected at random and scored.
Also, one random field was selected in sections where all staining
appeared intense. At least 200 tumour cells were scored per  40
field. The sample was classified as intratumoral HGF-positive when
X50% of the tumour cells in a given specimen were positively
stained for HGF, and it was classified as intratumoral HGF-
negative when o50% of the cells were stained. In addition, the
sample was classified as stromal HGF-positive when X50% of the
stromal cells of tumours in a given specimen were positively
stained for HGF, and it was classified as stromal HGF-negative
when o50% of the stromal cells were stained.
Since a homogeneous cytoplasmic staining pattern appeared in
c-Met-stained tumour cells, c-Met staining was scored by staining
intensity as reported previously (Jin et al, 1997; Ramirez et al,
2000). Staining intensity was classified as grade 0 (no staining),
grade 1 (weak staining), grade 2 (moderately strong staining),
grade 3 (very strong staining), or grade 4 (extremely strong
staining). The sample was classified as intratumoral c-Met-positive
when the intensity of c-Met-stained tumour cells in a given
specimen was greater than grade 1. All other samples of c-Met-
stained tumour cells were classified as intratumoral c-Met-
negative.
The rate of tumour proliferation was evaluated by the
percentage of carcinoma cells that stained positive for Ki-67 in a
given specimen scored using the Ki-67 proliferation index.
Tumours with a Ki-67 proliferation index X25% were classified
as high Ki-67, while tumours with o25% were classified as low Ki-
67. For microvessel quantification, the three most vascularised
areas detected by CD34 immunostaining were initially selected
under  40 field, and  200 field (0.785mm
2 per field), and
microvessels were counted in each of these areas. The average
count for three  200 fields was recorded as the IMD. Tumours
with IMD X90 were classified as hypervascular, while tumours
with IMD o90 were classified as hypovascular (Masuya et al,
2001).
Statistical analysis
The overall cancer-specific survival was defined from the date of
operation to the date of cancer-related death. Statistical signifi-
cances in the expression of HGF, c-Met, Ki-67, and IMD in relation
to several clinical and pathologic parameters were assessed using a
t-test and w
2 test. The Kaplan–Meier method was used to estimate
the probability of overall survival as a function of time, and
survival periods were compared using a log-rank test. Analysis
using the Cox regression model was performed to study the effects
of different variables on survival rate. All P-values were based on
two-tailed statistical analysis, and P-values o0.05 were taken to
indicate the statistical significance.
RESULTS
Hepatocyte growth factor expression in NSCLCs
Hepatocyte growth factor staining of tumour or stromal cells
appeared in the form of a heterogeneous cytoplasmic staining
pattern. Among the 88 carcinomas examined for HGF expression
in tumour cells, 22 carcinomas (25.0%) were intratumoral HGF-
positive, and 66 carcinomas (75.0%) were intratumoral HGF-
negative (Table 1 and Figure 1A). There was no significant
difference in intratumoral HGF expression according to tumour
histology, tumour status, nodal status, and tumour differentiation.
With regard to HGF expression in the stromal cells of tumours, 14
carcinomas (15.9%) were stromal HGF-positive and 74 carcinomas
(84.1%) were stromal HGF-negative (Table 1 and Figure 1B,C).
There was also no significant difference in stromal HGF expression
according to tumour histology, tumour status, nodal status, and
tumour differentiation. In addition, there was no correlation
between the percentage of HGF-positive tumour cells and HGF-
positive stromal cells in each NSCLC (r¼0.066, P¼0.5431).
c-Met expression in NSCLCs
c-Met-stained tumour cells showed a homogeneous cytoplasmic
staining pattern with variable intensity. In contrast, no carcinoma
exhibited positive c-Met staining in stromal cells. Of the 88
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Met-positive, and 52 carcinomas (59.1%) were intratumoral c-Met-
negative (Table 1 and Figure 1D–G). There was no significant
difference in intratumoral c-Met expression according to tumour
histology, tumour differentiation, and nodal status. However, the
frequency of intratumoral c-Met-positive tumours was signifi-
cantly higher for T2–4 tumours than for T1 tumours (50.9 vs
25.7%, P¼0.0185).
Ki-67 proliferation index in NSCLCs
The mean value of the Ki-67 proliferation index among the 88
NSCLCs studied was 44.2731.0. In all, 44 carcinomas (50.0%) had
a high Ki-67 index and 44 carcinomas (50.0%) had a low Ki-67
index (Figure 1H). Of the 46 adenocarcinomas, 16 tumours
(34.8%) had a high Ki-67 index and 22 tumours (75.9%) of the 29
squamous cell carcinomas had a high Ki-67 index. Among the 13
large cell carcinomas, six tumours (46.2%) had a high Ki-67 index.
The frequency of tumours with a high Ki-67 index was significantly
greater for squamous cell carcinomas than for adenocarcinomas
(Po0.001).
Tumour vascularity in NSCLCs
The mean IMD value in the 88 NSCLCs was 97.7752.8. In total, 45
carcinomas (51.1%) were hypervascular and 43 carcinomas
(48.9%) were hypovascular. Of the 46 adenocarcinomas 31
tumours (67.4%) were hypervascular, and eight tumours (27.6%)
among the 29 squamous cell carcinomas were hypervascular. Also,
six tumours (46.2%) of the 13 large-cell carcinomas were
hypervascular. The frequency of hypervascular tumours was
significantly higher for adenocarcinomas than for squamous cell
carcinomas (Po0.001).
Ki-67 proliferation index in relation to HGF and c-Met
status
There was no difference in Ki-67 index between intratumoral HGF-
positive tumours and intratumoral HGF-negative tumours
(44.7730.8 vs 42.5732.4) with regard to intratumoral HGF
expression. However, the Ki-67 proliferation index was
59.9724.5 among stromal HGF-positive tumours, and 41.2731.4
among stromal HGF-negative tumours. The Ki-67 proliferation
index was significantly greater in stromal HGF-positive tumours
than in stromal HGF-negative tumours (P¼0.0386). Of the 14
stromal HGF-positive tumours, 11 tumours (78.6%) had a high Ki-
67 index, and 33 tumours (44.6%) among the 74 stromal HGF-
negative tumours had a high Ki-67 index. The frequency of
tumours with a high Ki-67 index was significantly greater for
stromal HGF-positive tumours than for stromal HGF-negative
tumours (P¼0.0197, Figure 2A).
The Ki-67 proliferation index was 48.5728.8 among intratu-
moral c-Met-positive tumours, and 41.3732.4 among intratumoral
c-Met-negative tumours. Of the 36 intratumoral c-Met-positive
tumours, 23 tumours (63.9%) had a high Ki-67 index, while 21
tumours (40.4%) of the 52 c-Met-negative tumours had a high
Ki-67 index. The frequency of tumours with a high Ki-67 index
was significantly greater for intratumoral c-Met-positive tumours
than for intratumoral c-Met-negative tumours (P¼0.0301,
Figure 2B).
There was no significant correlation between the percentage of
HGF-positive stromal cells and the percentage of c-Met-positive
tumour cells in each NSCLC (r¼0.030, P¼0.7802). Therefore, the
88 NSCLCs examined were classified into three groups according
to stromal HGF status and intratumoral c-Met status; one group in
which six patients had tumours that exhibited both positive
stromal HGF and intratumoral c-Met expression; a second group
in which 38 patients had tumours which demonstrated either
Table 1 Distribution of 88 non-small-cell lung cancer patients according to HGF and c-Met status
Intratumoral HGF Stromal HGF Intratumoral c-Met
Variables n Positive Negative P-value Positive Negative P-value Positive Negative P-value
Tumor status
T1 35 11 24 0.2577 7 28 0.3939 9 26 0.0185
T2, T3, T4 53 11 42 7 46 27 26
Nodal status
N0 56 17 39 0.1247 10 46 0.5086 21 35 0.3895
N1, N2, N3 32 5 27 4 28 15 17
Pathological stage
Stage I 46 15 31 0.0756 9 37 0.7416 14 32 0.0169
Stage II 10 1 9 1 9 2 8
Stage IIIA 12 0 12 2 10 8 4
Stage IIIB 20 6 14 2 18 12 8
Differentiation
Well 30 8 22 0.0717 2 28 0.1606 10 20 0.2299
Moderately 30 11 19 5 25 16 14
Poorly 28 3 25 7 21 10 18
Histology
Adenocarcinoma 46 16 30 0.0687 5 41 0.0520 22 24 0.1099
Squamous cell carcinoma 29 5 24 4 25 12 17
Large-cell carcinoma 13 1 12 5 8 2 11
Total number of patients 88 22 66 14 74 36 52
HGF¼hepatocyte growth factor.
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yFigure 1 Immunohistochemical staining of human non-small-cell lung cancer tissues using the avidin–biotin–peroxidase complex procedure (original
magnification,  100). (A) An intratumoral HGF-positive squamous cell carcinoma. (B) A stromal HGF-positive squamous cell carcioma. (C) A stromal
HGF-negative adenocarcinoma. (D) An intratumoral c-Met-positive adenocarcinoma. (E) An intratumoral c-Met-positive squamous cell carcinoma. (F)A n
intratumoral c-Met-negative squamous cell carcinoma. (G) An intratumoral c-Met-negative adenocarcinoma. (H) Ki-67 staining of an adenocarcinoma.
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third group where 44 patients had tumours that showed negative
expression for both HGF and c-Met. The frequency of tumours
with a high Ki-67 index was 83.3% in the first group, 63.2% in the
second group, and 34.0% in the third group. The frequency of high
Ki-67 tumours in the third group was significantly lower than that
for the other two groups (P¼0.0086 and 0.0209, respectively,
Figure 2C).
Tumour vascularity in relation to HGF and c-Met
No significant difference was found in IMD between intratumoral
HGF-positive and intratumoral HGF-negative tumours
(103.2741.4 vs 96.0755.9). In addition, there was no significant
difference in IMD between stromal HGF-positive and stromal
HGF-negative tumours (106.6760.2 vs 95.9751.4). Also, no
significant difference was evident in IMD between intratumoral
c-Met-positive and intratumoral c-Met-negative tumours
(103.4758.9 vs 89.3741.4).
Overall survival of NSCLC patients in relation to HGF and
c-Met status
The 5-year survival rates of the 88 NSCLC patients according to
intratumoral HGF status, stromal HGF status, and c-Met status are
shown in Table 2. There was no significant difference in survival
among the patients in relation to intratumoral HGF status. In
addition, there was also no significant difference with relation to
stromal HGF status.
With respect to intratumoral c-Met status, however, the 5-year
survival rate of patients with intratumoral c-Met-positive tumours
was significantly lower than that for patients with intratumoral c-
Met-negative tumours (33.8 vs 63.2%, P¼0.0095, Figure 3A). Also,
the 5-year survival rate for patients with c-Met-positive adeno-
carcinomas was significantly lower than that for patients with c-
Met-negative adenocarcinomas (33.9 vs 65.9%, P¼0.0399,
Figure 3B). Furthermore, the 5-year survival rate for patients with
c-Met-positive tumours was significantly lower than that for
patients with c-Met-negative tumours, especially in T2–4 tumours
(21.0 vs 53.2%, P¼0.0481, Figure 3C). A univariate analysis using
the Cox regression model demonstrated that intratumoral c-Met
status was a significant factor for predicting the prognosis of
NSCLC patients (relative risk¼2.642, P¼0.0029).
Since a correlation between the Ki-67 proliferation index and
both intratumoral c-Met and stromal HGF expression was
demonstrated, the survival of NSCLC patients according to
intratumoral c-Met and stromal HGF status was analysed
(Figure 3D). The 5-year survival rate was 61.4% for patients with
both negative tumours, 45.3% for patients with either type of
positive tumours, and 0% for patients with both positive tumours.
The 5-year survival rate for patients with both positive tumours
was significantly lower than that for patients with either type of
positive tumours, and that for patients with both negative tumours
(P¼0.0183 and 0.0011, respectively).
DISCUSSION
Hepatocyte growth factor was discovered to be a mitogen for
hepatocytes (Nakamura et al, 1989), and subsequently found to be
identical to the scatter factor (SF), which destroys epithelial cell
adhesion and promotes cell motility (Weidner et al, 1991). To date,
HGF is known to be a multifunctional cytokine which induces cell
proliferation (Montesano et al, 1991), motility (Weidner et al,
1990), angiogenesis (Bussolino et al, 1992), and morphogenesis
(Brinkmann et al, 1995), in a wide variety of normal and neoplastic
cells. In addition, its receptor is c-Met (Bottaro et al, 1991), a
transmembrane tyrosine kinase receptor encoded by the proto-
oncogene c-Met (Park et al, 1987).
Overexpression of HGF and/or c-Met has been reported in
various human cancers, including NSCLCs (Olivero et al, 1996)
and breast cancers (Edakuni et al, 2001). Some tumour cell-derived
factors, such as interleukin-1, basic fibroblast growth factor, and
tumour necrosis factor-a, are involved in the overexpression of
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Figure 2 (A) Tumour proliferation rate in relation to stromal HGF
status in NSCLCs. (B) Tumour proliferation rate in relation to intratumoral
c-Met status in NSCLCs. (C) Tumour proliferation rate in relation to
stromal HGF status and intratumoral c-Met status in NSCLCs.
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1997). In addition, one study revealed that cells transformed by the
ras oncogene overexpressed c-Met (Webb et al, 1998). Thus, such
growth factors produced in stromal cells interact with the
receptors expressed on tumour cells (paracrine pattern) (Chung,
1995). In addition, malignant tumour cells also often produce
growth factors and their associated receptors (autocrine pattern)
(Edakuni et al, 2001). Therefore, the HGF/c-Met pathway plays an
important role during tumour progression in a paracrine pattern
and/or autocrine pattern.
Several clinical studies of the HGF/c-Met pathway in NSCLCs
demonstrated that its expression was associated with a poor
survival rate of NSCLC patients (Ichimura et al, 1996; Takanami
et al, 1996; Siegfried et al, 1997). However, the precise mechanisms
which control their behavior in NSCLCs are still not fully
understood, partly because they have a variety of function and
also because they originate from tumour or stromal cells.
Therefore, we undertook this study using immunohistochemistry
to investigate the relationship between the HGF/c-Met pathway
and both tumour growth and angiogenesis.
This study initially revealed that HGF expression appeared
independently in tumour cells and/or stromal cells. In contrast, c-
Met expression appeared only in tumour cells and not stromal
cells, as reported by previous studies in human cancers (Ichimura
et al, 1996; Kurimoto et al, 1998; Edakuni et al, 2001). Olivero et al,
1996 reported that c-Met staining was homogeneously distributed
in a tumour mass, and that there was no staining of c-Met in
normal lung tissue. However, HGF staining was detected in the
cytoplasm of grouped cells scattered in tumour tissue, as reported
previously (Olivero et al, 1996). These findings present here agreed
well with these previous results. Therefore, we used different
criteria to classify HGF and c-Met staining, respectively.
We then evaluated the rate of tumour proliferation using the Ki-
67 labeling index (Gerde et al, 1984; Scagliotti et al, 1993). Ki-67
antibody recognizes the nuclear antigen expressed during G1, S,
G2, and M phases of the cell cycle and not during the resting (G0)
phase. The present study demonstrated significant association
between the Ki-67 index and both stromal HGF and intratumoral
c-Met expression. However, there was no correlation between the
Ki-67 index and intratumoral HGF expression, as demonstrated by
the low percentage of high Ki-67 index tumours among stromal
HGF and intratumoral c-Met-negative NSCLCs. In addition, the
frequency of intratumoral c-Met-positive tumours was signifi-
cantly higher for T2–4 tumours than for T1 tumours. These results
indicated that the interaction between stromal cell-derived HGF
and tumour cell-derived c-Met promote tumour cell proliferation
in a paracrine manner. To our knowledge, this study is the first
clinical report on NSCLCs that demonstrates a correlation between
the HGF/c-Met pathway and tumour growth through tumour–
stromal interaction, as similarly reported for breast cancers
(Edakuni et al, 2001).
The HGF/c-Met pathway is reported to be associated with
angiogenesis (Bussolino et al, 1992), which is considered
to be essential for tumour growth and metastasis (Folkman,
1990, 1995). Our previous studies revealed that tumour vascularity
in NSCLCs is associated with intratumoral expression of VEGF-A
(Masuya et al, 2001), interleukin-8 (Masuya et al, 2001), neural-
cadherin (Nakashima et al, 2003), and that tumour vascularity is
correlated with the survival rate of NSCLC patients (Nakashima
et al, 2003). However, the present study did not show a correlation
between the HGF/c-Met pathway and tumour vascularity in
NSCLCs.
Previous clinical studies have reported that overexpression of
HGF and/or c-Met is associated with the survival rate of patients
with malignant tumours, including NSCLCs (Ichimura et al, 1996;
Takanami et al, 1996; Siegfried et al, 1997), breast cancers
(Edakuni et al, 2001), and thyroid cancers (Ramirez et al, 2000).
However, few studies on NSCLCs have evaluated both HGF and c-
Met expression, and distinguished tumour cell derived-expression
from stromal cell-derived expression. The present study demon-
Table 2 Five-year survival rate of 88 non-small-cell lung cancer patients according to HGF and c-Met status
Intratumoral HGF Stromal HGF c-Met
Variables Positive Negative P-value Positive Negative P-value Positive Negative P-value
Tumor status
T1 80.8 69.1 0.2889 83.3 71.3 0.5920 72.9 72.5 0.7980
T2, T3, T4 40.4 35.8 0.6386 17.1 39.4 0.3220 21.0 53.2 0.0481
Nodal status
N0 68.3 66.8 0.5148 66.7 67.9 0.8604 52.0 76.2 0.1146
N1, N2, N3 26.7 21.6 0.7577 0.0 24.9 0.2969 7.9 34.7 0.0817
Pathological stage
Stage I 78.3 75.7 0.6677 75.0 77.5 0.6903 68.9 80.0 0.4205
Stage II 100.0 37.5 0.4440 0.0 50.0 0.5072 0.0 50.0 0.0941
Stage IIIA 0.0 9.1 40.9999 0.0 11.1 0.1635 14.3 0.0 0.3456
Stage IIIB 0.0 27.9 0.2223 0.0 20.7 0.4443 9.3 42.9 0.3808
Differentiation
Well 58.3 57.1 0.5321 50.0 59.0 0.6339 40.0 67.7 0.1269
Moderately 58.3 58.6 0.6983 33.3 61.1 0.4406 41.7 75.5 0.1184
Poorly 66.7 33.8 0.4610 57.1 31.6 0.3316 12.5 49.4 0.0599
Histology
Adenocarcinoma 54.1 49.7 0.4936 75.0 49.6 0.5097 33.9 65.9 0.0399
Squamous cell carcinoma 75.0 55.8 0.3609 0.0 67.2 0.1573 41.3 71.8 0.1464
Large-cell carcinoma 100.0 33.3 0.3846 60.0 25.0 0.2568 0.0 45.5 0.0610
Total 60.3 48.6 0.1735 50.7 52.2 0.8409 33.8 63.2 0.0095
HGF¼hepatocyte growth factor.
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positive tumours is significantly lower than that of patients with
intratumoral c-Met-negative tumours, and that the survival rate for
patients with tumours with both positive expression of intratu-
moral c-Met and stromal HGF is significantly lower than that for
patients with tumours with either positive expression, or with
tumours with both negative expression. Although a multivariate
analysis using intratumoral c-Met status and tumour status was
not proper because of tumour status depending on intratumoral c-
Met expression, a univariate analysis using the Cox regression
model demonstrated that intratumoral c-Met status had a
significant effect on the prognosis of NSCLC patients. These
results agreed with a previous clinical study on breast cancers
(Edakuni et al, 2001).
In conclusion, the present study on NSCLCs has demonstrated
that intratumoral c-Met and stromal HGF expression promote
tumour growth. Furthermore, intratumoral c-Met expression is a
potent prognostic factor of NSCLC patients. A recent study
reported that c-Met can also be activated by semaphoring 4D to
trigger invasive cell growth (Giordano et al, 2002). Although
further studies are necessary to clarify these mechanisms
(Trusolino et al, 2001), these studies on the HGF/c-Met pathway
will aid the development of new therapeutic strategies for the
treatment of NSCLC cancer patients. For example, the HGF
antagonist NK4 suppresses tumour growth and could improve the
clinical outcome of patients with carcinomas that exhibit over-
expression of HGF and/or c-Met (Date et al, 1998; Kuba et al,
2000).
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